1059 related articles for article (PubMed ID: 29848108)
1. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
[TBL] [Abstract][Full Text] [Related]
3. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
Skljarevski V; Oakes TM; Zhang Q; Ferguson MB; Martinez J; Camporeale A; Johnson KW; Shan Q; Carter J; Schacht A; Goadsby PJ; Dodick DW
JAMA Neurol; 2018 Feb; 75(2):187-193. PubMed ID: 29255900
[TBL] [Abstract][Full Text] [Related]
4. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
[TBL] [Abstract][Full Text] [Related]
5. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.
Hu B; Li G; Li X; Wu S; Yu T; Li X; Zhao H; Jia Z; Zhuang J; Yu S
J Headache Pain; 2022 Jul; 23(1):90. PubMed ID: 35896988
[TBL] [Abstract][Full Text] [Related]
6. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
Förderreuther S; Zhang Q; Stauffer VL; Aurora SK; Láinez MJA
J Headache Pain; 2018 Dec; 19(1):121. PubMed ID: 30594122
[TBL] [Abstract][Full Text] [Related]
7. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
[TBL] [Abstract][Full Text] [Related]
8. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
Detke HC; Goadsby PJ; Wang S; Friedman DI; Selzler KJ; Aurora SK
Neurology; 2018 Dec; 91(24):e2211-e2221. PubMed ID: 30446596
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
10. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
Ailani J; Andrews JS; Rettiganti M; Nicholson RA
J Headache Pain; 2020 Oct; 21(1):123. PubMed ID: 33069214
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
13. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
[TBL] [Abstract][Full Text] [Related]
14. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
Ament M; Day K; Stauffer VL; Skljarevski V; Rettiganti M; Pearlman E; Aurora SK
J Headache Pain; 2021 Feb; 22(1):6. PubMed ID: 33549036
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
Bangs ME; Kudrow D; Wang S; Oakes TM; Terwindt GM; Magis D; Yunes-Medina L; Stauffer VL
BMC Neurol; 2020 Jan; 20(1):25. PubMed ID: 31952501
[TBL] [Abstract][Full Text] [Related]
16. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
[TBL] [Abstract][Full Text] [Related]
17. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
Detke HC; Millen BA; Zhang Q; Samaan K; Ailani J; Dodick DW; Aurora SK
Headache; 2020 Feb; 60(2):348-359. PubMed ID: 31710104
[TBL] [Abstract][Full Text] [Related]
18. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.
Dodick DW; Doty EG; Aurora SK; Ruff DD; Stauffer VL; Jedynak J; Dong Y; Pearlman EM
Cephalalgia; 2021 Mar; 41(3):340-352. PubMed ID: 33143451
[TBL] [Abstract][Full Text] [Related]
19. Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial.
Schwedt TJ; Myers Oakes TM; Martinez JM; Vargas BB; Pandey H; Pearlman EM; Richardson DR; Varnado OJ; Cobas Meyer M; Goadsby PJ
Neurol Ther; 2024 Feb; 13(1):85-105. PubMed ID: 37948006
[TBL] [Abstract][Full Text] [Related]
20. Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.
Stauffer VL; Wang S; Voulgaropoulos M; Skljarevski V; Kovacik A; Aurora SK
Headache; 2019 Jun; 59(6):834-847. PubMed ID: 30942898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
